Anti-Vascular Endothelial Growth Factor Therapy with or Without Initial Steroid Therapy for Macular Edema in Branch Retinal Vein Occlusion

References

• Noma H, Yasuda K, Shimura M. Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion. J Ophthalmol. 2019;5185128.
   PubMedGoogle Scholar
• Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol. 2011;152(4):669–677 e661.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology. 2010;117(6):1102–1112 e1101.
   PubMed Web of Science ®Google Scholar
• Noma H, Yasuda K, Shimura M. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. Eur J Ophthalmol. 2021;31(1):204–210.
   PubMed Web of Science ®Google Scholar
• Noma H, Mimura T, Yasuda K, et al. Cytokines and recurrence of macular edema after intravitreal ranibizumab in patients with branch retinal vein occlusion. Ophthalmologica. 2016;236(4):228–234.
   PubMed Web of Science ®Google Scholar
• Lashay A, Riazi-Esfahani H, Mirghorbani M, Yaseri M. Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis. J Ophthalmic Vis Res. 2019;14(3):336–366.
   PubMed Web of Science ®Google Scholar
• Patil NS, Hatamnejad A, Mihalache A, Popovic MM, Kertes PJ, Muni RH. Anti-vascular endothelial growth factor treatment compared with steroid treatment for retinal vein occlusion: a meta-analysis. Ophthalmologica. 2022;245(6):500–515.
   PubMed Web of Science ®Google Scholar
• Sakanishi Y, Tamaki K, Mashimo K, Sakuma T, Ebihara N. Relationship between recurrence of macular edema due to branch retinal vein occlusion and changes in choroidal thickness. Ophthalmic Res. 2021;64(3):363–368.
   PubMed Web of Science ®Google Scholar
• Noma H, Mimura T, Shimada K. Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. BMC Ophthalmol. 2014;14:67.
   PubMed Web of Science ®Google Scholar
• Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial growth factor receptors-1 and −2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci. 2014;55(6):3878–3885.
   PubMed Web of Science ®Google Scholar
• Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye. 2016;30(8):1084–1090.
   PubMed Web of Science ®Google Scholar
• Osaka R, Muraoka Y, Nakano Y, et al. One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Jpn J Ophthalmol. 2020;64(6):605–612.
   PubMed Web of Science ®Google Scholar
• Cheung CM, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in dia betic patients with and without retinopathy. Mol Vis. 2012;18:830–837.
   PubMed Web of Science ®Google Scholar
• Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):155–159.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, Harino S, Sone T, Hori S. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol. 2010;88(6):646–651.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K, Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res. 2011;36(3):256–263.
   PubMed Web of Science ®Google Scholar
• Maltsev DS, Kulikov AN, Volkova YV, Burnasheva MA, Vasiliev AS. Retinal macrophage-like cells as a biomarker of inflammation in retinal vein occlusions. J Clin Med. 2022;11(24):56.
   Web of Science ®Google Scholar
• Koss M, Pfister M, Rothweiler F, et al. Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography. Open Ophthalmol J. 2013;7:11–17.
   PubMedGoogle Scholar
• Pfister M, Rothweiler F, Michaelis M, et al. Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion. Clin Ophthalmol. 2013;7:1061–1067.
   PubMedGoogle Scholar
• McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147(5):838–846, 846 e831–832.
   Web of Science ®Google Scholar
• Kurtz RM, Elner VM, Bian ZM, Strieter RM, Kunkel SL, Elner SG. Dexamethasone and cyclosporin A modulation of human retinal pigment epithelial cell monocyte chemotactic protein-1 and interleukin-8. Invest Ophthalmol Vis Sci. 1997;38(2):436–445.
   PubMed Web of Science ®Google Scholar
• Sadowski T, Steinmeyer J. Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-1alpha treated articular chondrocytes. Biochem Pharmacol. 2002;64(2):217–227.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Nishiwaki A, Morita H, Miyake T, Ogura Y. Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci. 2007;48(6):2831–2836.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96(19):10836–10841.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Kiryu J, Tsujikawa A, et al. Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003;44(1):332–341.
   PubMed Web of Science ®Google Scholar
• Nan K, Sun S, Li Y, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010;94(5):654–658.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014;121(9):1783–1789.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Hirano Y, Tomiyasu T, et al. Collateral vessels on optical coherence tomography angiography in eyes with branch retinal vein occlusion. Br J Ophthalmol. 2019;103(10):1373–1379.
   PubMed Web of Science ®Google Scholar
• Cehofski LJ, Kruse A, Bøgsted M, et al. Retinal proteome changes following experimental branch retinal vein occlusion and intervention with ranibizumab. Exp Eye Res. 2016;152:49–56.
   PubMed Web of Science ®Google Scholar
• Iwao K, Inatani M, Kawaji T, Koga T, Mawatari Y, Tanihara H. Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. J Glaucoma. 2007;16(2):251–256.
   PubMed Web of Science ®Google Scholar
• Kawamura R, Inoue M, Shinoda H, et al. Incidence of increased intraocular pressure after subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2011;27(3):299–304.
   PubMed Web of Science ®Google Scholar